Company Portage Biotech Inc OTC Bulletin Board

Equities

CA09852M1014

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Shareholders

Holdings

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

03/06	Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	MT
03/06	Investors Await Key Manufacturing Data as US Futures Nudge Higher in Monday's Premarket Session	MT

Portage Biotech Inc. develops pharmaceutical and biotech products through to clinical proof of concept focusing on unmet clinical needs. After proof of concept, the Company will look to sell or license the products to various pharmaceutical companies for further development through to commercialization. The Company's research and development work is primarily carried out through approximately two subsidiaries, including Portage Pharmaceuticals Ltd (PPL) and Biohaven Pharmaceutical Holding Company Limited (Biohaven). The Company also holds interests in Sentien Biotechnologies Inc., a regenerative medicine company. PPL focuses on discovering and developing cell permeable peptide (CPP) therapies to normalize gene expression, restore function and improve medical outcomes. Biohaven is engaged in the identification and development of glutamatergic agents for treatment-resistant neuropsychiatric disorders. Its product pipeline includes PPL-003, BHV-0223 and BHV-4157.

Managers	Title	Age	Since
Ian Walters CEO	Chief Executive Officer	57	01/16/01
Allan Shaw DFI	Director of Finance/CFO	59	12/20/12
Steve Innaimo COO	Chief Operating Officer	-	08/19/08
Robert Kramer CTO	Chief Tech/Sci/R&D Officer	72	08/19/08
Justin Fairchild PRN	Corporate Officer/Principal	-	18/22/18
Brian Wiley PRN	Corporate Officer/Principal	56	15/22/15
Joseph Ciavarella AUD	Comptroller/Controller/Auditor	68	01/20/01

Members of the board	Title	Age	Since
Gregory Bailey FOU	Founder	68	01/73/01
Steven Mintz BRD	Director/Board Member	57	06/16/06
Robert Glassman BRD	Director/Board Member	62	-
Mark Simon BRD	Director/Board Member	62	15/22/15
Ian Walters CEO	Chief Executive Officer	57	01/16/01
Linda Kozick BRD	Director/Board Member	66	15/22/15

Name	Equities	%	Valuation
Gregory Bailey 17.20 %	3,402,195	17.20 %	2 M $
Estate of Mellon James 15.33 %	3,032,821	15.33 %	1 M $
Armistice Capital LLC 8.420 %	1,665,885	8.420 %	797 959 $
Ian Walters 1.246 %	246,516	1.246 %	118 081 $
Bison Wealth LLC 1.079 %	213,398	1.079 %	102 218 $
Robert Kramer 0.7431 %	147,009	0.7431 %	70 417 $
Steven Mintz 0.2796 %	55,311	0.2796 %	26 494 $
Peak6 Investments LLC 0.2793 %	55,263	0.2793 %	26 471 $
Millennium Management LLC 0.1659 %	32,827	0.1659 %	15 724 $
Renaissance Technologies LLC 0.1600 %	31,663	0.1600 %	15 167 $

Name	Equities	%	Valuation
INTENSITY THERAPEUTICS, INC. 4.70%	644,229	4.70%	3,201,818 $

Portage Biotech, Inc.

Clarence Thomas Building

VG1110, Road Town

http://www.portagebiotech.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+47.02%	5.66TCr
IQVIA HOLDINGS INC.	-7.83%	3.96TCr
LONZA GROUP AG	+36.02%	3.93TCr
CELLTRION, INC.	-9.38%	2.83TCr
ICON PUBLIC LIMITED COMPANY	+11.26%	2.64TCr
ALNYLAM PHARMACEUTICALS, INC.	-17.07%	2.01TCr
UNITED THERAPEUTICS CORPORATION	+29.94%	1.25TCr
MEDPACE HOLDINGS, INC.	+28.54%	1.25TCr
BIO-TECHNE CORPORATION	-1.56%	1.22TCr

Other Biotechnology & Medical Research